The ubiquity of the pink ribbon campaign, the prevalence of precision medicine as a recurring theme in every scientific and medical journal, and the very fact that BRCA has entered the lexicon of society – globally – suggests that breast cancer testing is standard. Indeed, something that has been part of everyday life for some… Read article →
NGS and bioinformatics
QIAGEN at AMP Europe 2018 Video: NGS Assay Development Lead Dr. Simon Hughes discusses recent studies for the QIAact Lung All in One panel and the Myeloid panel for the GeneReader NGS workflow at AMP Europe 2018.
QIAGEN had the pleasure of taking part in an NGS Bioinformatics Challenge run by the German Society for Pathology on the 9th and 10th of November in Halle, Germany. Three commercial organizations were supplied with vcf files from twelve samples sequenced using Illumina MiSeq™ Systems and the IonTorrent platform at Erlangen, Cologne Berlin. The identity… Read article →
Myeloid malignancies are complex clonal diseases arising in hematopoietic stem or progenitor cells. These heterogenous disorders comprise many different subtypes such as myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and acute myeloid leukemia (AML). There is a growing need for molecular profiling of these blood and bone marrow disorders to provide better definition… Read article →
For decades, tissue-conserving surgery coupled with chemotherapy (either preceding or following surgery, depending on the size of the tumor(s)) followed by radiation has been the standard of care for the majority of cancers. Over the past fifteen years, chemoradiotherapy (concurrently dosing a patient with chemotherapy and radiation) has improved the overall survival rates especially for… Read article →
Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.
Recent statistics have placed lung cancers as the second most common form of cancer and by far the leading cause of cancer death in both men and women (1). With poor survival rates using current treatments, gaining a better understanding of the underlying molecular drivers of lung cancers has been the focus of numerous research… Read article →
Meet us there! The 22nd EHA congress 2017 is just around the corner, and we’re excited to see you there from June 22 – 25 in Madrid, Spain! Here at QIAGEN, we are proud to be part of the collaborative effort to improve cancer care. The EHA congress is the perfect event for QIAGEN to remind… Read article →
Cutting edge approaches such as NGS are the future of biomarker testing, but require expertise from industry leaders like QIAGEN to develop. QIAGEN’s biomarker assays are designed to ease the challenges faced by those who perform the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to deliver multiple benefits… Read article →
New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016 Charlotte, North Carolina, and Hilden, Germany, November 9, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the… Read article →
QIAGEN’s broad portfolio of Sample to Insight solutions for NGS were a focus at the QIAGEN booth and industry symposium at this year’s annual Congress of the European Society of Pathology. The XXXI International Congress of the International Academy of Pathology (IAP) and 28th Congress of the European Society of Pathology (ESP) was hosted for… Read article →
One of the greatest challenges in applying NGS to clinical research is ensuring that you are generating relevant results from your precious samples. Wading through the vast amount of data generated from NGS to find the actionable content can be daunting. One solution is the use of targeted gene panels that enable you to focus… Read article →
Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples Hilden, Germany, and Germantown, Maryland, June 1, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN’s GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights… Read article →
The global DNA sequencing capacity is increasing 3x-5x per year, leading to an unprecedented flood of biological data. Already, the output of biological data amounts to 15 petabytes a year (the equivalent of >3 million DVDs) and its amount doubles every 9 months, making it hard for scientists to keep up and put the information… Read article →
Meet us there to discuss how our next-generation oncology solutions can take you from sample to result ASCO is just around the corner, and we’re looking forward to seeing you from June 3–7 in Chicago! The theme of this year’s meeting is “Collective wisdom: The future of patient-centered care and research”. Here at QIAGEN, we… Read article →